Havaldar Amarja Ashok, Prakash Jay, Kumar Sanjeev, Sheshala Kaladhar, Chennabasappa Abhilash, Thomas Ria Rachel, Sushmitha Ea Chinny, Khan Mohd Saif, Kumar Raman, Kindo Srishti, Singh Ritu, Kartik Munta, Swamy Akshay Hiruyur Manjunatha, Raj John Michael, Thomas Tinku, Selvam Sumithra
Department of Critical Care Medicine, St John's Medical College Hospital, Bengaluru, Karnataka, India.
Department of Critical Care Medicine, Rajendra Institute of Medical Sciences (RIMS), Ranchi, Jharkhand, India.
Indian J Crit Care Med. 2022 Nov;26(11):1184-1191. doi: 10.5005/jp-journals-10071-24349.
Emergency authorization and approval were given for the coronavirus disease-19 (COVID-19) vaccines. The efficacy reported after phase III trials were 70.4% and 78% for Covishield and Covaxin, respectively.In this study, we aim to analyze the risk factors, which were associated with mortality in critically ill COVID-19-vaccinated patients admitted into intensive care unit (ICU).
This study was conducted from April 1, 2021 to December 31, 2021 across five centers in India. Patients who had received either one or two doses of any of the COVID vaccines and developed COVID-19 were included. The ICU mortality was a primary outcome.
A total of 174 patients with COVID-19 illness were included in the study. The mean age was 57 years standard deviation (SD 15). Acute physiology, age and chronic health evaluation (APACHE II) score and the sequential organ failure assessment (SOFA) score were 14 (8-24.5) and 6 (4-8), respectively. Multiple variable logistic regression showed patients who have received a single dose [odds ratio (OR): 2.89, confidence interval (CI): 1.18, 7.08], neutrophil:lymphocyte (NL) ratio (OR: 1.07, CI: 1.02,1.11), and SOFA score (OR: 1.18, CI: 1.03,1.36) were associated with higher mortality.
The mortality in the vaccinated patients admitted to the ICU was 43.68% due to COVID illness. The mortality was lower in patients who had received two doses.
Havaldar AA, Prakash J, Kumar S, Sheshala K, Chennabasappa A, Thomas RR et al Demographics and Clinical Characteristics of COVID-19-vaccinated Patients Admitted to ICU: A Multicenter Cohort Study from India (PostCoVac Study-COVID Group). Indian J Crit Care Med 2022;26(11):1184-1191.
新型冠状病毒肺炎（COVID-19）疫苗获得了紧急授权和批准。III期试验后报告的Covishield和Covaxin疫苗的效力分别为70.4%和78%。在本研究中，我们旨在分析与入住重症监护病房（ICU）的COVID-19疫苗接种重症患者死亡率相关的危险因素。
本研究于2021年4月1日至2021年12月31日在印度的五个中心进行。纳入接受过一剂或两剂任何COVID疫苗并感染COVID-19的患者。ICU死亡率是主要结局。
本研究共纳入174例COVID-19疾病患者。平均年龄为57岁（标准差15）。急性生理学、年龄和慢性健康评估（APACHE II）评分及序贯器官衰竭评估（SOFA）评分分别为14（8 - 24.5）和6（4 - 8）。多变量逻辑回归显示，接受单剂疫苗的患者[比值比（OR）：2.89，置信区间（CI）：1.18，7.08]、中性粒细胞与淋巴细胞（NL）比值（OR：1.07，CI：1.02，1.11）以及SOFA评分（OR：1.18，CI：1.03，1.36）与较高死亡率相关。
因COVID疾病入住ICU的接种疫苗患者死亡率为43.68%。接受两剂疫苗的患者死亡率较低。
哈瓦尔达尔AA，普拉卡什J，库马尔S，谢沙拉K，钦纳巴萨帕A，托马斯RR等。入住ICU的COVID-19疫苗接种患者的人口统计学和临床特征：一项来自印度的多中心队列研究（PostCoVac研究 - COVID组）。《印度危重症医学杂志》2022；26(11)：1184 - 1191。
